Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Drug Preparations Undermine Europe’s Regulatory System

Executive Summary

Genevieve Michaux and Luca Salernitano examine the complexities and concerns surrounding the flourishing practice of preparing medicines for patients by pharmacies and hospitals in the EU. They say it undermines the very essence of the EU drug evaluation system and the regimes adopted to incentivize the development of medicinal products for rare diseases and pediatric patients.

You may also be interested in...



Dutch Move On Pharmacy Compounding Could Deter Orphan Drug Launches

Medicines prepared in pharmacies are now exempt from patent law in the Netherlands, giving pharmacists greater scope to prepare their own versions of patented medicines.

EU Avastin Court Ruling Deals Yet Another Blow To Novartis

In the latest in a string of knockbacks for both Novartis and Roche, the EU’s highest court has said that the Italian authorities are within their rights to reimburse Roche’s Avastin for wet AMD, even though it is not approved for that indication.

Eight Months And Counting: Santen Still Waiting For Final Marketing Decision On Drug Fast-Tracked By EMA

It has been eight months since the European Medicines Agency recommended market approval for a drug that was reviewed under its fast-track mechanism, but the sponsor has yet to receive a final decision from the European Commission. The company ran into problems when seeking to renew the drug's orphan status before approval.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS124339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel